Use fundamental data analysis to check out all available financial ratios of Medigus Ltd to find out if markets are presently mispricing the entity. We found twenty-seven available fundamentals for Medigus Ltd which can be compared to its peers in the industry. To make sure the equity is not overpriced, please verify all Medigus Ltd fundamentals including its Shares Outstanding, Price to Book, Revenue, as well as the relationship between Price to Earning and Price to Sales . Use Medigus Ltd to protect your portfolios against small markets fluctuations. The stock experiences normal downward trend and little activity. Check odds of Medigus Ltd to be traded at S46.43 in 30 days.
Medigus Ltd Company Summary
Medigus Ltd competes with Itamar Medical, Endymed Ltd, BioView Ltd, Insuline Medical. Medigus Ltd., a medical device company, develops, produces, and markets minimally invasive endo-surgical tools and direct visualization technology in the United States, Europe, Asia, and internationally. Medigus Ltd. was founded in 1999 and is headquartered in Omer, Israel. Medigus Ltd operates under Medical Devices classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 27 people.
Medigus Ltd Price to Book vs Return On Asset
Medigus Ltd is regarded third in price to book category among related companies. It is regarded fifth in return on asset category among related companies .
|Price to Book ( times )|
|Return On Asset ( % )|
Medigus Ltd Systematic Risk
Medigus Ltd May 21, 2019 Opportunity Range
|Value At Risk||(4.75)|